Gregory D. Gorgas, President and CEO of Artelo Biosciences (ARTL), commented on the results of the second quarter, “We are very pleased with the momentum across our pipeline, highlighted by the growing body of evidence supporting our first-in-class FABP5 inhibitor, ART26.12. The successful completion of our Phase 1 SAD study demonstrated positive safety and pharmacokinetics, laying the groundwork for our upcoming MAD study. We are also on track to report Phase 2 data from our CAReS study of ART27.13 during the current third quarter and to collect data demonstrating dual-action efficacy of our preclinical candidate ART12.11 in treating depression and cognitive decline to support our plans to initiate human trials early next year. These achievements reflect our commitment to addressing large unmet medical needs through novel science and thoughtful clinical development,” concluded Mr. Gorgas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences receives notice of allowance from European patent office
- Artelo Biosciences Partners with ABK Labs for Strategic Growth
- Artelo Biosciences announces private placement to initiate Solana treasury
- Artelo Biosciences receives MHRA guidance for Phase 1 trial of ART12.11
- Artelo Biosciences Announces At-The-Market Offering Agreement